Inventor

ODEN FELIX

DE9 patents

⚠️ This page may combine multiple inventors who share the name “ODEN FELIX”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT

4 patents

US10144782B2Dec 4, 2018

Humanized antibodies against CD269 (BCMA)

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT8 citations80

US11820829B2Nov 21, 2023

Humanized antibodies against CD269 (BCMA)

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT0 citations59

US11667722B2Jun 6, 2023

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT0 citations57

US10851172B2Dec 1, 2020

Humanized antibodies against CD269 (BCMA)

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT0 citations48

AC IMMUNE SA

3 patents

US11306089B2Apr 19, 2022

Gamma-carboline compounds for the detection of Tau aggregates

AC IMMUNE SA0 citations58

US10865207B2Dec 15, 2020

Compounds for imaging Tau protein aggregates

AC IMMUNE SA0 citations47

US10835624B2Nov 17, 2020

Compounds for imaging Tau protein aggregates

AC IMMUNE SA0 citations47

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN

1 patent

US10189906B2Jan 29, 2019

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN7 citations79

Max-Delbrück-Centrum für Molekulare Medizin

1 patent

US10745486B2Aug 18, 2020

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

Max-Delbrück-Centrum für Molekulare Medizin 3 citations63